TEST BANK FOR INTRODUCTORY CLINICAL PHARMACOLOGY 12TH EDITION BY
SUSAN FORD CHAPTER 1-54 | COMPLETE GUIDE NEWEST VERSION 2023
,Contents
Chapter 01: General Principles of Pharmacology ..................................................................................... 4
Chapter 02, Administration of Drugs ...................................................................................................... 28
Chapter 03, Making Drug Dosing Safer ................................................................................................... 51
Chapter 04, The Nursing Process ............................................................................................................ 70
Chapter 05, Patient and Family Teaching ............................................................................................... 90
Chapter 06, Antibacterial Drugs: Sulfonamides .................................................................................... 114
Chapter 07, Antibacterial Drugs That Disrupt the Bacterial Cell Wall .................................................. 135
Chapter 08, Antibacterial Drugs That Interfere with Protein Synthesis ............................................... 159
Chapter 09, Antibacterial Drugs That Interfere With DNA/RNA Synthesis .......................................... 177
Chapter 10, Antitubercular Drugs ......................................................................................................... 197
Chapter 11, Antiviral Drugs ................................................................................................................... 216
Chapter 12, Antifungal and Antiparasitic Drugs ................................................................................... 237
Chapter 13, Nonopioid Analgesics: Salicylates and Nonsalic- ylates .................................................... 259
Chapter 14, Nonopioid Analgesics: Nonsteroidal An- ti-Inflammatory Drugs (NSAIDs) and Migraine
Headache Medications ......................................................................................................................... 278
Chapter 15, Opioid Analgesics .............................................................................................................. 298
Chapter 16, Anesthetic Drugs ............................................................................................................... 315
Chapter 17, Central Nervous System Stimulants .................................................................................. 333
Chapter 18, Antidementia Drugs .......................................................................................................... 351
Chapter 19, Antianxiety Drugs .............................................................................................................. 371
Chapter 20, Sedatives and Hypnotics ................................................................................................... 390
Chapter 21, Antidepressant Drugs ........................................................................................................ 409
Chapter 22, Antipsychotic Drugs .......................................................................................................... 430
Chapter 23, Adrenergic Drugs ............................................................................................................... 448
Chapter 24, Adrenergic Blocking Drugs ................................................................................................ 467
Chapter 25, Cholinergic Drugs .............................................................................................................. 484
Chapter: 26, Cholinergic Blocking Drugs ............................................................................................... 503
Chapter 27, Antiparkinson Drugs .......................................................................................................... 523
Chapter 28, Antiepileptics..................................................................................................................... 544
Chapter 29, Skeletal Muscle, Bone, and Joint Disorder Drugs.............................................................. 563
Chapter 30, Upper Respiratory System Drugs ...................................................................................... 583
Chapter 31, Lower Respiratory System Drugs ...................................................................................... 603
,Chapter 32, Diuretics ............................................................................................................................ 622
Chapter 33, Antihyperlipidemic Drugs .................................................................................................. 640
Chapter 34, Antihypertensive Drugs ..................................................................................................... 658
Chapter 35, Antianginal and Vasodilating Drugs .................................................................................. 678
Chapter 36, Anticoagulant and Thrombolytic Drugs ............................................................................ 696
Chapter 37, Cardiotonic and Antiarrhythmic Drugs ............................................................................. 715
Chapter 38, Upper Gastrointestinal System Drugs ............................................................................... 733
Chapter 39, Lower Gastrointestinal System Drugs ............................................................................... 751
Chapter 40, Antidiabetic Drugs ............................................................................................................. 771
Chapter 41, Pituitary and Adrenocortical Hormones ........................................................................... 790
Chapter 42, Thyroid and Antithyroid Drugs .......................................................................................... 811
Chapter 43, Male and Female Hormones ............................................................................................. 828
Chapter 44, Uterine Drugs .................................................................................................................... 847
Chapter 45, Menopause and Andropause Drugs.................................................................................. 867
Chapter: 46, Urinary Tract Anti-Infectives and Other Urinary Drugs ................................................... 887
Chapter 47, Vaccines............................................................................................................................. 904
Chapter 48, Immunostimulants and Immunomodulators .................................................................... 923
Chapter 49: Immune Blockers............................................................................................................... 941
Chapter 50, Traditional Chemotherapy ................................................................................................ 956
Chapter 51: Immune Modulating Therapies......................................................................................... 973
Chapter 52, Skin Disorder Topical Drugs .............................................................................................. 986
Chapter 53, Otic and Ophthalmic Preparations .................................................................................. 1005
Chapter 54, Fluids, Electrolytes, and Parenteral Therapy .................................................................. 1023
,Chapter 01: General Principles of Pharmacology
1. After teaching a group of students about the basics of pharmacology, the students will be able to
choose which aspect as the most critical to remember?
A) Drug name
B) Drug class
C) Drug action
D) Drug source
ANSWER:C
Rationale: Pharmacology is the study of drugs and its action on living organisms. Thus, an essential
aspect of pharmacology is drug action. An understanding of the drug name, drug class, and drug source
is important, but the most critical aspect related to pharmacology is how the drug acts in the body.
Question Format: Multiple Choice
Learning Objective: 1
Cognitive Level: Apply
Client Needs: Physiological Integrity: Pharmacological Therapies
Integrated Process: Teaching/Learning
Reference: p. 3, Introduction
2. A nurse suspects the client had an adverse reaction to a prescribed medication due to an interaction
with an unreported over-the-counter supplement. Which action by the nurse will best assist in
preventing future similar incidents?
A) File a report with MedWatch
B) File a report with the State Board of Nursing
C) Instruct the client to avoid combining medications in the future
D) Document the incident and report it to the health care provider
,ANSWER:A
Rationale: Nurses play an important role in monitoring for adverse reactions. Therefore, it is important
to submit reports, even if there is uncertainty about the cause–effect relationship. The FDA protects the
identity of those who voluntarily report adverse reactions. Question Format: Multiple Choice
Learning Objective: 9
Cognitive Level: Apply
Client Needs: Safe and Effective Care Environment: Safety and InfectionControl
Integrated Process: Clinical Problem-solving Process (Nursing Process) Reference: p. 7, Box 1.1
MedWatch and Reporting Adverse Events
3. A nurse is assessing a client and notes the client has developed swelling of the eyelids and lips after
administration of a prescribed medication. What does the nurse interpret this finding to specifically
indicate?
A) Mild allergic reaction
B) Anaphylactic shock
C) Angioedema
D) Drug idiosyncrasy
ANSWER:C
Rationale: Angioedema is a type of allergic drug reaction manifested by the collection of fluid in the
subcutaneous tissues, most commonly affecting the eyelids, lips, mouth, and throat. Allergic reactions
can be manifested by a wide range of signs and symptoms such as itching, rashes, and hives.
Anaphylactic shock is a serious allergic reaction that requires immediate medical attention. Drug
idiosyncrasy describes any unusual or abnormal reaction to a drug, one that is different from the one
normally expected.
Question Format: Multiple Choice
, Learning Objective: 5
Cognitive Level: Apply
Client Needs: Physiological Integrity: Reduction of Risk Potential Integrated
Process: Clinical Problem-solving Process (Nursing Process) Reference: p. 12,
Allergic Drug Reactions
4. The nurse is preparing to teach a client about a new drug which is in the fourth phase of
development. Which activity will the nurse explain best illustrates this phase? A) Health care providers
report adverse effects to FDA.
B) Healthy volunteers are involved in the test.
C) In vitro tests are performed using human cells.
D) The drug is given to clients with the disease.
ANSWER:A
Stuvia.com - The Marketplace to Buy and Sell your Study Material
Rationale: The postmarketing surveillance phase of drug development encourages health care
professionals to report adverse effects of drugs to the FDA using MedWatch. Phase 1 of clinical testing
involves 20 to 100 healthy volunteers. In vitro testing of the drug on human or animal cells is done in the
pre-FDA phase. In Phase 2 of clinical testing, the drug is given to clients with the disease for which the
drug is manufactured.
Question Format: Multiple Choice
Learning Objective: 4
Cognitive Level: Apply
Client Needs: Health Promotion and Maintenance
Integrated Process: Teaching/Learning Reference: p. 7, Concept Mastery Alert
5. A nurse is assessing a pregnant client who admits to having a cocaine addiction. Which condition
of the baby after birth should the nurse explain and preparethe client for?
SUSAN FORD CHAPTER 1-54 | COMPLETE GUIDE NEWEST VERSION 2023
,Contents
Chapter 01: General Principles of Pharmacology ..................................................................................... 4
Chapter 02, Administration of Drugs ...................................................................................................... 28
Chapter 03, Making Drug Dosing Safer ................................................................................................... 51
Chapter 04, The Nursing Process ............................................................................................................ 70
Chapter 05, Patient and Family Teaching ............................................................................................... 90
Chapter 06, Antibacterial Drugs: Sulfonamides .................................................................................... 114
Chapter 07, Antibacterial Drugs That Disrupt the Bacterial Cell Wall .................................................. 135
Chapter 08, Antibacterial Drugs That Interfere with Protein Synthesis ............................................... 159
Chapter 09, Antibacterial Drugs That Interfere With DNA/RNA Synthesis .......................................... 177
Chapter 10, Antitubercular Drugs ......................................................................................................... 197
Chapter 11, Antiviral Drugs ................................................................................................................... 216
Chapter 12, Antifungal and Antiparasitic Drugs ................................................................................... 237
Chapter 13, Nonopioid Analgesics: Salicylates and Nonsalic- ylates .................................................... 259
Chapter 14, Nonopioid Analgesics: Nonsteroidal An- ti-Inflammatory Drugs (NSAIDs) and Migraine
Headache Medications ......................................................................................................................... 278
Chapter 15, Opioid Analgesics .............................................................................................................. 298
Chapter 16, Anesthetic Drugs ............................................................................................................... 315
Chapter 17, Central Nervous System Stimulants .................................................................................. 333
Chapter 18, Antidementia Drugs .......................................................................................................... 351
Chapter 19, Antianxiety Drugs .............................................................................................................. 371
Chapter 20, Sedatives and Hypnotics ................................................................................................... 390
Chapter 21, Antidepressant Drugs ........................................................................................................ 409
Chapter 22, Antipsychotic Drugs .......................................................................................................... 430
Chapter 23, Adrenergic Drugs ............................................................................................................... 448
Chapter 24, Adrenergic Blocking Drugs ................................................................................................ 467
Chapter 25, Cholinergic Drugs .............................................................................................................. 484
Chapter: 26, Cholinergic Blocking Drugs ............................................................................................... 503
Chapter 27, Antiparkinson Drugs .......................................................................................................... 523
Chapter 28, Antiepileptics..................................................................................................................... 544
Chapter 29, Skeletal Muscle, Bone, and Joint Disorder Drugs.............................................................. 563
Chapter 30, Upper Respiratory System Drugs ...................................................................................... 583
Chapter 31, Lower Respiratory System Drugs ...................................................................................... 603
,Chapter 32, Diuretics ............................................................................................................................ 622
Chapter 33, Antihyperlipidemic Drugs .................................................................................................. 640
Chapter 34, Antihypertensive Drugs ..................................................................................................... 658
Chapter 35, Antianginal and Vasodilating Drugs .................................................................................. 678
Chapter 36, Anticoagulant and Thrombolytic Drugs ............................................................................ 696
Chapter 37, Cardiotonic and Antiarrhythmic Drugs ............................................................................. 715
Chapter 38, Upper Gastrointestinal System Drugs ............................................................................... 733
Chapter 39, Lower Gastrointestinal System Drugs ............................................................................... 751
Chapter 40, Antidiabetic Drugs ............................................................................................................. 771
Chapter 41, Pituitary and Adrenocortical Hormones ........................................................................... 790
Chapter 42, Thyroid and Antithyroid Drugs .......................................................................................... 811
Chapter 43, Male and Female Hormones ............................................................................................. 828
Chapter 44, Uterine Drugs .................................................................................................................... 847
Chapter 45, Menopause and Andropause Drugs.................................................................................. 867
Chapter: 46, Urinary Tract Anti-Infectives and Other Urinary Drugs ................................................... 887
Chapter 47, Vaccines............................................................................................................................. 904
Chapter 48, Immunostimulants and Immunomodulators .................................................................... 923
Chapter 49: Immune Blockers............................................................................................................... 941
Chapter 50, Traditional Chemotherapy ................................................................................................ 956
Chapter 51: Immune Modulating Therapies......................................................................................... 973
Chapter 52, Skin Disorder Topical Drugs .............................................................................................. 986
Chapter 53, Otic and Ophthalmic Preparations .................................................................................. 1005
Chapter 54, Fluids, Electrolytes, and Parenteral Therapy .................................................................. 1023
,Chapter 01: General Principles of Pharmacology
1. After teaching a group of students about the basics of pharmacology, the students will be able to
choose which aspect as the most critical to remember?
A) Drug name
B) Drug class
C) Drug action
D) Drug source
ANSWER:C
Rationale: Pharmacology is the study of drugs and its action on living organisms. Thus, an essential
aspect of pharmacology is drug action. An understanding of the drug name, drug class, and drug source
is important, but the most critical aspect related to pharmacology is how the drug acts in the body.
Question Format: Multiple Choice
Learning Objective: 1
Cognitive Level: Apply
Client Needs: Physiological Integrity: Pharmacological Therapies
Integrated Process: Teaching/Learning
Reference: p. 3, Introduction
2. A nurse suspects the client had an adverse reaction to a prescribed medication due to an interaction
with an unreported over-the-counter supplement. Which action by the nurse will best assist in
preventing future similar incidents?
A) File a report with MedWatch
B) File a report with the State Board of Nursing
C) Instruct the client to avoid combining medications in the future
D) Document the incident and report it to the health care provider
,ANSWER:A
Rationale: Nurses play an important role in monitoring for adverse reactions. Therefore, it is important
to submit reports, even if there is uncertainty about the cause–effect relationship. The FDA protects the
identity of those who voluntarily report adverse reactions. Question Format: Multiple Choice
Learning Objective: 9
Cognitive Level: Apply
Client Needs: Safe and Effective Care Environment: Safety and InfectionControl
Integrated Process: Clinical Problem-solving Process (Nursing Process) Reference: p. 7, Box 1.1
MedWatch and Reporting Adverse Events
3. A nurse is assessing a client and notes the client has developed swelling of the eyelids and lips after
administration of a prescribed medication. What does the nurse interpret this finding to specifically
indicate?
A) Mild allergic reaction
B) Anaphylactic shock
C) Angioedema
D) Drug idiosyncrasy
ANSWER:C
Rationale: Angioedema is a type of allergic drug reaction manifested by the collection of fluid in the
subcutaneous tissues, most commonly affecting the eyelids, lips, mouth, and throat. Allergic reactions
can be manifested by a wide range of signs and symptoms such as itching, rashes, and hives.
Anaphylactic shock is a serious allergic reaction that requires immediate medical attention. Drug
idiosyncrasy describes any unusual or abnormal reaction to a drug, one that is different from the one
normally expected.
Question Format: Multiple Choice
, Learning Objective: 5
Cognitive Level: Apply
Client Needs: Physiological Integrity: Reduction of Risk Potential Integrated
Process: Clinical Problem-solving Process (Nursing Process) Reference: p. 12,
Allergic Drug Reactions
4. The nurse is preparing to teach a client about a new drug which is in the fourth phase of
development. Which activity will the nurse explain best illustrates this phase? A) Health care providers
report adverse effects to FDA.
B) Healthy volunteers are involved in the test.
C) In vitro tests are performed using human cells.
D) The drug is given to clients with the disease.
ANSWER:A
Stuvia.com - The Marketplace to Buy and Sell your Study Material
Rationale: The postmarketing surveillance phase of drug development encourages health care
professionals to report adverse effects of drugs to the FDA using MedWatch. Phase 1 of clinical testing
involves 20 to 100 healthy volunteers. In vitro testing of the drug on human or animal cells is done in the
pre-FDA phase. In Phase 2 of clinical testing, the drug is given to clients with the disease for which the
drug is manufactured.
Question Format: Multiple Choice
Learning Objective: 4
Cognitive Level: Apply
Client Needs: Health Promotion and Maintenance
Integrated Process: Teaching/Learning Reference: p. 7, Concept Mastery Alert
5. A nurse is assessing a pregnant client who admits to having a cocaine addiction. Which condition
of the baby after birth should the nurse explain and preparethe client for?
